Selective depletion of activated T cells: the CD40L-specific antibody experience

The role of Inflammation in platelet activation (and in anti-neutrophil cytoplasmic antibody (ANCA) vasculitis)
Rashvand, S., Dishkelov, A. and Jurcevic, S. 2024. The role of Inflammation in platelet activation (and in anti-neutrophil cytoplasmic antibody (ANCA) vasculitis). GTH Congress 2024 – 68th Annual Meeting of the Society of Thrombosis and Haemostasis Research – Building Bridges in Coagulation. https://doi.org/10.1055/s-0044-1779178

microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells
Mortoglou, M., Miralles, F., Arisan, E.D., Dart, A., Jurcevic, S., Lange, S. and Uysal Onganer, P. 2022. microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells. International Journal of Molecular Sciences. 23 (3) 1275. https://doi.org/10.3390/ijms23031275

Epitope recognition of peptide-imprinted polymers for Regenerating protein 1 (REG1)
Lee, M.H., Thomas, J.L., Liao, C.L., Jurcevic, S., Crnogorac-Jurcevic, T. and Lin, H.Y. 2018. Epitope recognition of peptide-imprinted polymers for Regenerating protein 1 (REG1). Separation and Purification Technology. 192, pp. 213-219. https://doi.org/10.1016/j.seppur.2017.09.071

Polymers imprinted with three REG1B peptides for electrochemical determination of Regenerating Protein 1B, a urinary biomarker for pancreatic ductal adenocarcinoma
Jurcevic, S., Lee, M-H., Thomas, J.L., Liao, C-L., Crnogorac-Jurcevic, T. and Lin, H-Y. 2017. Polymers imprinted with three REG1B peptides for electrochemical determination of Regenerating Protein 1B, a urinary biomarker for pancreatic ductal adenocarcinoma. Microchimica Acta. 184 (6), p. 1773–1780. https://doi.org/10.1007/s00604-017-2169-4

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
Coffey, G., Rani, A., Betz, A., Pak, Y., Haberstock-Debic, H., Pandey, A., Hollenbach, S., Gretler, D.D., Mant, T., Jurcevic, S. and Simha, U. 2017. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. Journal of Clinical Pharmacology. 57 (2), pp. 194-210. https://doi.org/10.1002/jcph.794

Effects of multiple-dose ponesimod, a selective SIP1 receptor modulator, on lymphocyte subsets in healthy humans
Jurcevic, S., Juif, P.E., Hamid, C., Greenlaw, R., D'Ambrosio, D. and Dingemanse, J. 2016. Effects of multiple-dose ponesimod, a selective SIP1 receptor modulator, on lymphocyte subsets in healthy humans. Drug Design, Development and Therapy. 11, pp. 123-131. https://doi.org/10.2147/DDDT.S120399

The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
Jurcevic, S., Humfrey, C., Uddin, M., Warrington, S., Larsson, B. and Keen, C. 2015. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions. Br J Clin Pharmacol. . 80 (6), pp. 1324-36. https://doi.org/10.1111/bcp.12724

The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
Jakubowski, J.A., Zhou, C., Winters, K.J., Lachno, D.R., Howard, J., Payne, C.D., Mant, T., Jurcevic, S. and Frelinger, A.L. 2015. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease. Platelets. 26 (5), pp. 474-479. https://doi.org/10.3109/09537104.2014.940887

FRA2 is a STAT5 target gene regulated by IL-2 in human CD4 T cells
Rani, A., Greenlaw, R., Runglall, M., Jurcevic, S. and John, S. 2014. FRA2 is a STAT5 target gene regulated by IL-2 in human CD4 T cells. PLoS ONE. 9 (2), p. e90370. https://doi.org/10.1371/journal.pone.0090370

A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation
Jakubowski, J.A., Zhou, C., Jurcevic, S., Winters, K.J., Lachno, D.R., Frelinger, A.L., Gupta, N., Howard, J., Payne, C.D. and Mant, T. 2014. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thrombosis Research. 133 (2), pp. 190-5. https://doi.org/10.1016/j.thromres.2013.12.008

Antibody combination therapy targeting CD25, CD70 and CD8 reduces islet inflammation and improves glycaemia in diabetic mice
Alkhamis, T., Barbic, J., Crnogorac-Jurcevic, T., Greenlaw, R.E., Peakman, M. and Jurcevic, S. 2012. Antibody combination therapy targeting CD25, CD70 and CD8 reduces islet inflammation and improves glycaemia in diabetic mice. Clinical & Experimental Immunology. 170 (2), p. 139–148 PMC3482360. https://doi.org/10.1111/j.1365-2249.2012.04651.x

The Role of the Fc Region in CD70-specific Antibody Effects on Cardiac Transplant Survival
Jurcevic, S., Shariff, H., Greenlaw, R.E., Meader, L., Gardner, N., Yagita, H., Coccia, M. and Mamode, N. 2011. The Role of the Fc Region in CD70-specific Antibody Effects on Cardiac Transplant Survival. Transplantation. 92 (11), pp. 1194-1201. https://doi.org/10.1097/TP.0b013e3182347ecd

An Antibody Combination That Targets Activated T Cells Extends Graft Survival in Sensitized Recipients
Jurcevic, S. 2008. An Antibody Combination That Targets Activated T Cells Extends Graft Survival in Sensitized Recipients. American Journal of Transplantation. 8 (11), pp. 2272-2282. https://doi.org/10.1111/j.1600-6143.2008.02393.x

Transplant tolerance: models, concepts and facts
Monk, N.J., Hargreaves, R.E.G., Simpson, E., Dyson, J.P. and Jurcevic, S. 2006. Transplant tolerance: models, concepts and facts. Journal of Molecular Medicine. 84 (4), pp. 295-304. https://doi.org/10.1007/s00109-005-0006-4

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation
Jurcevic, S., Braselmann, S., Taylor, V., Zhao, H., Wang, S. and Masuda, E.S. 2006. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. Journal of Pharmacology and Experimental Therapeutics. 319 (3), pp. 998-1008 109058/3152109. https://doi.org/10.1124/jpet.106.109058

Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade
Monk, N.J., Hargreaves, R.E.G., Marsh, J.E., Farrar, C.A., Sacks, S.H., Millrain, M., Simpson, E., Dyson, J. and Jurcevic, S. 2003. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nature Medicine. 9 (10), pp. 1275-1280. https://doi.org/10.1038/nm931